Literature DB >> 10199060

Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants.

H M Hamer1, H H Morris.   

Abstract

Anticonvulsant hypersensitivity syndrome, a potentially fatal but rare reaction, manifests as rash, fever, tender lymphadenopathy, hepatitis, and eosinophilia. To manage hypersensitivity syndrome successfully, one must recognize the symptoms early, stop the offending drug immediately, and substitute a safe, alternative anticonvulsant medication. Hypersensitivity syndrome has not been described in patients taking benzodiazepines or the newer anticonvulsants gabapentin or topiramate, and these appear to be safe substitutes for drugs that cause the reaction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10199060     DOI: 10.3949/ccjm.66.4.239

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  4 in total

1.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

Review 2.  Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management.

Authors:  Alberto Verrotti; Daniela Trotta; Carmela Salladini; Francesco Chiarelli
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

4.  Phenobarbital-induced autoimmune haemolytic anaemia, thrombocytopenia and peripheral lymphadenomegaly due to reactive lymphoid hyperplasia in a cat.

Authors:  Michelle Walton-Clark; Victoria Travail; Matthew Best
Journal:  JFMS Open Rep       Date:  2022-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.